Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04116047 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)

Study acronym: CompARE
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 7 of 38 sitesv8
  2. Re-verified, no change to tracked fieldsv7
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 38 of 38 sites
    v6
  4. Primary completion date: Jan 2023 to Dec 2026
    • Study sites: 33 to 38
    • Study completion date: Jan 2023 to Dec 2030
    • Collaborators: 1 to 2
    v5
  5. Enrollment target: 695 to 785
    • Interventions: Cisplatin (Drug), Dose-escalated radiotherapy (Procedure), Durvalumab (Drug), Radiotherapy (Procedure) to Cisplatin (Drug), Durvalumab (Drug), Radiotherapy (Procedure)
    • Site details revised at 3 of 33 sites
    • Study arms: 3 to 2
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Re-verified, no change to tracked fieldsv3
  2. Study sites: 30 to 33v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
CompARE is a multicentre, phase III open-label randomised controlled trial using an adaptive, Multi-Arm, Multi-Stage (MAMS) design.
Trial Details
NCT Number NCT04116047
Lead Sponsor University of Birmingham
Collaborators: AstraZeneca, Cancer Trials Ireland
Conditions
(from sponsor)		 Oropharyngeal Cancer
Related terms Oropharyngeal Neoplasms
Enrollment 785 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov